Xenetic Biosciences Reports Third Quarter Financial Results and Provides Business Update
Xenetic Biosciences Announces the Closing of its $10M Public Offering
Xenetic Biosciences Announces Nasdaq Listing of its Common Stock and Pricing of $10M Public Offering
Xenetic Biosciences Reports Positive Topline Data from Third Cohort of Phase 2 Dose-Escalation Trial of ErepoXen® for Anemia
Xenetic Biosciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference
Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer
Xenetic Biosciences Announces Collaboration with Excivion Ltd., UK, to Develop a Novel Combined Zika and Dengue Vaccine
Xenetic Biosciences Appoints Jeffrey F. Eisenberg to the Board of Directors
Xenetic Biosciences Announces Reverse Stock Split in Preparation for Proposed Uplisting to Nasdaq Capital Market
